Search
Laquinimod
go.drugbank.com/drugs/DB06685InvestigationalIt is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. … Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.
Clenoliximab
go.drugbank.com/drugs/DB06241ExperimentalClenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.
AX200
go.drugbank.com/drugs/DB05093InvestigationalThe expression of the endogenous AX200 protein in the brain is increased after brain damage. … Thus, if this drug administered in the acute phase of stroke, the brain’s own protective action is supported.
SP1049C
go.drugbank.com/drugs/DB04978ExperimentalPreliminary data, in its first clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of the esophagus. … [A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review.
Categories: Compounds used in a research, industrial, or household settingMilveterol
go.drugbank.com/drugs/DB05043InvestigationalGSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
Enzastaurin
go.drugbank.com/drugs/DB06486InvestigationalEnzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of
Emricasan
go.drugbank.com/drugs/DB05408InvestigationalEmricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. … It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.
VLTS-589
go.drugbank.com/drugs/DB05430InvestigationalVLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Palifermin
go.drugbank.com/drugs/DB00039ApprovedInvestigationalIt is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]
Ranirestat
go.drugbank.com/drugs/DB05327InvestigationalIt has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy. … Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels